Latest Oncology News

Retifanlimab Emerges as Potential New SOC in Advanced SCAC

Retifanlimab Emerges as Potential New SOC in Advanced SCAC

January 7th 2025

Kyle Doherty

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

January 7th 2025

Megan Hollasch

Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.

Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients

Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients

January 7th 2025

Mount Sinai

Genetic markers for venetoclax could help personalize treatment and improve outcomes

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma

January 7th 2025

Ashling Wahner

A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.

Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations

Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations

January 7th 2025

Ashling Wahner

The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.

Latest Oncology Videos

Dr Borgen on the Strengths and Limitations of AI in Oncology Practice
Recent Guideline Updates in the Frontline Management of CLL
Dr Borgen on the Use of AI to Support Treatment Decision-Making in Oncology
SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety
DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma
Dr Brem on Odronextamab in Previously Untreated Patients, High-Risk Follicular Lymphoma
Dr DeAngelo on the FDA Approval of Blinatumomab Consolidation in CD19+, Ph– B-ALL
Dr DeAngelo on the Effect of Avapritinib on Bone Density in Advanced Systemic Mastocytosis
Dr Patel on ADCs in Early-Stage NSCLC
Dr Phull on the Efficacy and Safety of Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma
Dr Bhatnagar on AlloSCT Outcomes After Blinatumomab/Chemo in MRD-Negative B-ALL
Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Overcoming Disparities in Cancer Care
Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML
Dr LeVee on Immune-Related AEs Associated With ICIs in Early Breast Cancer
Dr Dreyling on the Role of ASCT in Ibrutinib-Containing First-Line Therapy for Younger Patients With MCL
Dr van Meerten on the Efficacy and Safety of Brexu-Cel in BTK Inhibitor–Naive R/R MCL
Dr Strickler on the Development of Telisotuzumab Adizutecan in MET-Amplified Gastric Cancer
Potential Next-Generation Therapies for Lung LCNEC
Insights Into Ongoing Investigational Studies in Lung LCNEC
Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease
Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel
Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

All Oncology News

Amivantamab Plus Lazertinib Improves OS in EGFR-Mutant Advanced NSCLC

January 7th 2025

Caroline Seymour

Amivantamab plus lazertinib prolonged overall survival vs osimertinib as first-line therapy in locally advanced or metastatic, EGFR-mutant NSCLC.

Flonoltinib Maleate Provides Durable Spleen Reduction and Symptom Improvement in Myelofibrosis

January 7th 2025

Courtney Flaherty

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS

January 7th 2025

Jax DiEugenio

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

January 7th 2025

Ashley Chan

Armin Ghobadi, MD, discusses the safety profile of WT-7 in heavily pretreated relapsed/refractory T-ALL and LBL.

Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD

January 7th 2025

Yvonne Mowery, MD, PhD

Dr Mowery discusses the SU2C-SARC032 trial of pembrolizumab plus preoperative radiotherapy and surgery in patients with soft-tissue sarcoma.

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

January 6th 2025

Chris Ryan

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

January 6th 2025

Courtney Flaherty

Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL

January 6th 2025

Ashley Chan

Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.

New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers

January 6th 2025

A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

January 6th 2025

Chris Ryan

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC

January 6th 2025

Courtney Flaherty

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

January 6th 2025

Kyle Doherty

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma

January 6th 2025

Jax DiEugenio

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

January 6th 2025

Chris Ryan

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Patient Factors Drive IO Combination Selection in Unresectable HCC

January 5th 2025

Ryan Scott

Aparna Parikh, MD, discusses the first-line treatment field for patients with hepatocellular carcinoma, highlighting notable immunotherapy options.

See All News